The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).
 
Guglielmo Vetere
No Relationships to Disclose
 
Ryan Sun
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Sanofi
 
Van Morris
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Incyte; Novartis; Regeneron; Scandion Oncology
Research Funding - Apollo Therapeutics (Inst); Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Bryan Kee
Stock and Other Ownership Interests - Medtronic
 
John Paul Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences; NaDeNo Nanosciences
Research Funding - BostonGene; Ikena Oncology (Inst)
 
Jason Willis
Honoraria - Bayer; Cor2Ed
Consulting or Advisory Role - Healios, K.K.
 
Maria Pia Morelli
No Relationships to Disclose
 
Alexey Sorokin
No Relationships to Disclose
 
Preeti Kanikarla Marie
No Relationships to Disclose
 
Robert Wolff
Honoraria - Conveners
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Michael Overman
Consulting or Advisory Role - 3T BioSciences; Agenus; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche/Genentech; Simcere; Summit Therapeutics
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Eduardo Vilar Sanchez
Consulting or Advisory Role - Abbvie; Guardant Health; Janssen Research & Development; Nouscom; Recursion Pharmaceuticals; Rising Tide Foundation
Research Funding - Janssen Research & Development; Nouscom
Patents, Royalties, Other Intellectual Property - The University of Texas MD Anderson Cancer Center, Vilar E, Chang K, Wu W, Bowen CM, Sinha K. Methods and Compositions Comprising MHC Class I Peptides, United States, 63/171,137, 4/6/2021, Filed (Provisional); The University of Texas MD Anderson Cancer Center, Vilar E, Wu W, Katayama H, Hanash S, Bommi P. Methods for Prognosing, Diagnosing, and Treating Colorectal Cancer, United States, 63/152,751, 2/23/2021, Filed (Provisional)
Travel, Accommodations, Expenses - Guardant Health; Janssen Research & Development
 
Ryan Huey
Honoraria - Aptitude Health; Clinical Care Targeted Communications LLC; Vizient
Travel, Accommodations, Expenses - Clinical Care Targeted Communications LLC; Vizient
 
Victoria Higbie
No Relationships to Disclose
 
Phat Le
Consulting or Advisory Role - Bayer
 
Yunyu Baig
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis
 
Christine Parseghian
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen
Research Funding - BioMed Valley Discoveries; Lilly; Verastem